3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
17
Ovarian Neoplasms
12
Neoplasms
8
Fallopian Tube Neoplasms
8
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
6
Pancreatic Neoplasms
6
Neoplasm Metastasis
6
Endometrial Neoplasms
4
Neuroendocrine Tumors
3
Glioma
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Recurrence
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Fanconi Anemia, Complementation Group D1
2
Cholangiocarcinoma
2
Uveal Melanoma
1
Urogenital Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
SCLC,Extensive Stage
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Platinum-sensitive Ovarian Cancer
1
Interventions
Fulvestrant
4
trastuzumab deruxtecan
2
elacestrant
2
Vinorelbine
2
toripalimab
1
talazoparib
1
ribociclib
1
pyrotinib
1
palbociclib
1
olaparib
1
exemestane
1
eribulin
1
disitamab vedotin
1
dalpiciclib
1
apatinib
1
abemaciclib
1
Selective Estrogen Receptor Modulators
1
Ritonavir
1
Radiotherapy
1
RAD1901
1
Letrozole
1
Itraconazole
1
Injections
1
Gonadotropin-Releasing Hormone
1
Everolimus
1
Capecitabine
1
Aromatase Inhibitors
1
Anastrozole
1
Ado-Trastuzumab Emtansine
1
AZD9833
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Advanced Breast Cancer
×
olaparib
×
Clear all
NCT05536128
2025-04-17
Post-CDK
Seoul National University Hospital
Phase 2
Recruiting
64 enrolled